ES008 / Elpiscience - LARVOL DELTA

Elpiscience Announces Studies Presented at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting....Our study showed that ES014, a bifunctional antibody–ligand trap which comprises an antibody targeting CD39 fused to a TGFβ receptor II ectodomain, can inhibit TGFβ activity and lead to cancer killing in ex vivo models....ES015-2 can completely block the interaction of NKG2A/CD94 with HLA-E, thereby inhibits HLA-E-induced NKG2A inhibitory signaling. Ligation of ES015-2 effectively potentiates the activation of NKG2C+ NK cells and T cells....ES008-a promotes NK cell-mediated destruction of tumor cells. ES008-a synergizes with CD47/SIRPα inhibitors in enhancing macrophage phagocytosis of tumor cells."

Preclinical • Oncology

ES008, a high affinity LILRB1 specific blocking antibody activates multiple immune cells to fight cancers (SITC 2023) - "ES008-a can also potently potentiate NK cells killing of tumor cells. Conclusions We have developed a functional anti-LILRB1 monoclonal antibody ES008-a that has great potential to activate multiple immune effector cells in the tumor microenvironment, leading to strong anti-tumor immunity."

Immune cell • Oncology • Solid Tumor • CD8 • LILRB1 • S100A8 • S100A9 • SIRPA

Elpiscience Announces Three Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...announced it will have three poster presentations at the SITC 2023 Annual Meeting taking place November 3-5, 2023, in San Diego. The posters will highlight its studies on three innovative molecules including a first-in-class NKG2A/NKG2C dual-targeting antibody ES015, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014 which has been proven to be able to deliver TGFβ 'trap' to CD39-expressing immune and stroma cells to reshape tumor microenvironment and rejuvenates antitumor immunity."

Preclinical • Oncology